NSG BioLabs, a Singapore-based provider of biotech co-working laboratory and office space, raised US$14.5M in funding.
The round was led by Celadon Partners with participation from ClavystBio.
The company intends to use the funds to augment its infrastructure, services, and benefits for residents, as well as support the expansion of its co-working laboratory and office spaces.
Led by CEO and Founder Daphne Teo, NSG BioLabs offers equipment, efficient operations, capital efficiency, the expertise of teams and global networks to assist life sciences companies. The R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 35,000 sq ft in the prime location of Biopolis in Singapore. Since 2019, the company has been assisting innovators in creating solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, and synthetic biology. It has helped over 40 companies as residents, of which the startups have achieved nearly US$400M funding in total alongside significant business milestones.
Commenting on the news, Daphne Tea said: “We are thankful for the recognition from our strategic investors, Celadon Partners and ClavystBio, and look forward to further empowering our residents in their innovation efforts through expanded facilities, enhanced value-add offerings, and greater exposure to valuable industry networking and mentorship experiences.”
FinSMEs
08/05/2024